Summary
E-pharma is a financial institution. The bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €497,097 and a net result of €108,372. Equity fluctuates too strongly from year to year to read a trend from it. Its solvency ranks better than 18% of 6,692 sector peers (NACE 64, financial year 2025). The company has been active since 2009 and the Belgian Official Gazette contains no insolvency or warning signals.
Overview
Overview
Official details
Source: KBO- Status
- Active since 02-12-2009 Normal situation
- Activity
- Activities of holding companies NACE 64210and 2 others
- Joint committee
- 313 Paritair Comité voor de apotheken en tarificatiediensten · annual accounts 2025
- Establishment unit
- 2.183.525.329 2660 Antwerpen, since 02-12-2009
- Financial year end
- 31 December
- Peppol
- Reachable since 21-03-2025
Board and ownership
Board
- AMBIXX BVDirector · permanent representative Marleen Slaets
Shareholders
- AMBIXX100%· score 872025 annual accounts of AMBIXX
- Holdings
- Shares in 3 companies including Apotheek Cauwenbergh and Apotheek De Voogt
Financial position
Financial institution: outside the modelBankruptcy probability: sector outside the model
Annual accounts 2025
- Profit
- €108,372
- Equity
- €497,097
- ▲ 27.9%
- Total assets
- €3.1m
- ▲ 4.8%
- Employees on 31-12-2025
- 13
- ▲ 30.0%
SignalsneutralLatest accounts filed on timeShow the evidence
Checked score
Outside the general model
Model not applicable to financial institutions
The Checked score measures liquidity, leverage and margins against the norms for trading and manufacturing companies. A bank, insurer or financial holding has a very different balance sheet. Those ratios and the score mean nothing here. So there is no financial strength either.
Bankruptcy probability within 12 months
The company is a financial institution: a bank, insurer or financial holding. Its balance sheet works differently from that of a trading or manufacturing company. A bankruptcy probability from the general model would mislead here.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
1 signal.
neutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 28-07-2026, 3 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
3 days early
2024
61 days late
2023
30 days late
2022
4 days early
2021
3 days early
2020
23 days late
2019
26 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 19 days after the deadline. In the sector (NACE 64), the median for financial year 2024 was 14 days before the deadline, and 28% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 28 July (4 of the last 5 accounts filed within 34 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
03-11-2026 today31-12-2026 year end31-07-2027 deadline
Financials
Financials · financial year 2025, abbreviated format
Annual accounts 2025 filed on 28-07-2026 at the NBB all 16 filings
Equity
€497,097▲ 27.9%
2024 · €388,725
Net result
€108,372
2024 · -€133,408
Total assets
€3.1m▲ 4.8%
2024 · €3.0m
Solvency
15.9%▲ 2.9pp
2024 · 13.1%
Multi-year overview
2018 to 2025, 8 financial yearsOperating result
€143,496
2025
20182025
Net result
€108,372
2025
middle half of the sector
20182025
Equity
€497,097
▲ 27.9%
2025
middle half of the sector
20182025
Total assets
€3.1m
▲ 4.8%
2025
middle half of the sector
20182025
Debt
€2.6m
▲ 1.3%
2025
20182025
Working capital
€279,334
2025
highest quarter of the sector
20182025
Solvency
15.9%
▲ 2.9pp
2025
lowest quarter of the sector
20182025
Current ratio
1.51
▲ 1.14
2025
middle half of the sector
20182025
Return on assets (ROA)
3.5%
▲ 8.0pp
2025
middle half of the sector
20182025
Staff (FTE)
8.8
▲ 6.0%
2025
highest quarter of the sector
20182025
Every figure per financial year
Every figure with its change against the financial year before
favourable
unfavourable
Line20182019202020212022202320242025
Operating result€0.2m-€0.1m▼ 19.0%€0.2m▲ 60.6%€0.009m▼ 96.1%€0.09m▲ 955%€0.03m▼ 67.1%-€0.07m€0.1m
Net result€0.1m-€0.08m▼ 21.3%€0.7mabove the sector's middle half▲ 773%-€0.02mbelow the sector's middle half€0.05mwithin the sector's middle half-€0.002mbelow the sector's middle half-€0.1mbelow the sector's middle half▼ 5,577%€0.1mwithin the sector's middle half
Equity€0.3m-€0.4m▲ 27.3%€1.0mwithin the sector's middle half▲ 187%€1.0mwithin the sector's middle half▼ 2.2%€1.1mwithin the sector's middle half▲ 5.2%€1.1mwithin the sector's middle half▼ 0.2%€0.4mwithin the sector's middle half▼ 63.3%€0.5mwithin the sector's middle half▲ 27.9%
Total assets€2.9m-€2.8m▼ 2.8%€2.9mwithin the sector's middle half▲ 3.8%€3.1mwithin the sector's middle half▲ 3.5%€3.1mwithin the sector's middle half▲ 1.5%€3.1mwithin the sector's middle half▼ 0.6%€3.0mwithin the sector's middle half▼ 3.2%€3.1mwithin the sector's middle half▲ 4.8%
Debt€2.6m-€2.5m▼ 6.1%€1.9m▼ 22.8%€2.0m▲ 6.5%€2.0m▼ 0.4%€2.0m▼ 0.8%€2.6m▲ 28.4%€2.6m▲ 1.3%
Working capital-€0.7m--€0.8m▼ 14.5%€0.2mwithin the sector's middle half-€0.09mwithin the sector's middle half-€0.2mbelow the sector's middle half▼ 107%-€0.3mbelow the sector's middle half▼ 60.3%-€1.2mbelow the sector's middle half▼ 303%€0.3mabove the sector's middle half
Solvency9.7%-12.7%▲ 3.0pp35.0%within the sector's middle half▲ 22.4pp33.1%within the sector's middle half▼ 1.9pp34.3%within the sector's middle half▲ 1.2pp34.5%within the sector's middle half▲ 0.1pp13.1%below the sector's middle half▼ 21.4pp15.9%below the sector's middle half▲ 2.9pp
Current ratio0.20-0.11▼ 0.081.39within the sector's middle half▲ 1.270.88within the sector's middle half▼ 0.500.80within the sector's middle half▼ 0.080.72within the sector's middle half▼ 0.080.37within the sector's middle half▼ 0.351.51within the sector's middle half▲ 1.14
Return on assets (ROA)3.4%-2.7%▼ 0.6pp22.9%above the sector's middle half▲ 20.1pp-0.8%below the sector's middle half▼ 23.6pp1.7%within the sector's middle half▲ 2.5pp-0.1%below the sector's middle half▼ 1.8pp-4.5%below the sector's middle half▼ 4.4pp3.5%within the sector's middle half▲ 8.0pp
Staff (FTE)4.2-5.5▲ 31.0%0.6below the sector's middle half▼ 89.1%8.3above the sector's middle half8.8above the sector's middle half▲ 6.0%
above
within
below
The sector band is the middle half of the companies in Financial service activities, except insurance and pension funding (NACE 64). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30.
The operating result for 2025 is a profit of €143,496, after a loss of €69,497 in 2024. It is the highest result since 2021.
Turnover and EBIT margin are not published. The abbreviated format does not require them. The turnover shown is an estimate from the gross margin.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €3.1m
Fixed assets
€2.3m ▼ 0.7%
Current assets
€828,144 ▲ 23.7%
Equity and liabilities €3.1m
Equity
€497,097 ▲ 27.9%
Debt
€2.6m ▲ 1.3%
Debt's share of the balance-sheet total falls from 86.9% to 84.1%. Equity and debt are higher.
Key figures and ratios
ROE
21.8%▲
2024 · -34.3%
Debt ≤ 1 year
€548,811▼
2024 · €1.8m
Debt > 1 year
€2.1m▲
2024 · €761,595
Income taxes
€2,595
Staff costs
€661,617▲
2024 · €152,146
Green means a favourable move, even when the figure itself falls, as with debt or debt to equity.
Staff
| Item | 31-12-2021 | 31-12-2024 | 31-12-2025 |
|---|---|---|---|
| Employees at the balance-sheet date | - | 10 | 13 |
| full-time | - | 2 | 2 |
| part-time | - | 8 | 11 |
| in full-time equivalents | - | 7.5 | 9.8 |
| Average over the year, in full-time equivalents | - | 8.3 | 8.8 |
| On a permanent contract | - | 10 | 13 |
| Joined | - | 11 | 6 |
| Left | - | 11 | 3 |
| Training hours | - | - | 88 |
Source: social balance sheet in the 2021 to 2025 annual accounts
Securities and guarantees
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Debts secured on the company's own assets | - | - | - | - | €1.4m |
| Carrying value of the other pledged assets | - | - | - | - | €1.9m |
Source: notes to the 2021 to 2025 annual accounts (statement of debts and off-balance-sheet rights and commitments)
Investments
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Tangible fixed assets | €29,783 | - | - | - | €7,256 |
| Financial fixed assets | €71,893 | - | - | - | - |
| Depreciation and write-downs of the year | €23,880 | €23,727 | €23,561 | €23,555 | €18,177 |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
Annual accounts
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | - | - | - | - | - | - | €2,844 | - |
| Remuneration, social security and pensions62 | - | - | - | -€175 | - | - | €152,146 | €661,617 | ▲ 335% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €18,216 | €18,203 | €18,316 | €23,880 | €23,727 | €23,561 | €23,555 | €18,177 | ▼ 22.8% |
| Other operating charges640/8 | - | - | - | €721 | €1,659 | €11,711 | €10,404 | €11,813 | ▲ 13.5% |
| Non-recurring operating charges66A | - | - | - | - | €1,108 | - | - | €7,265 | - |
| Gross operating margin9900 | €449,934 | €469,400 | €280,610 | €33,272 | €119,824 | €66,013 | €116,608 | €842,368 | ▲ 622% |
| Operating profit (loss)9901 | €173,585 | €140,540 | €225,722 | €8,845 | €93,330 | €30,741 | -€69,497 | €143,496 | - |
| Financial charges65/66B | - | - | - | €31,656 | €28,403 | €30,447 | €63,911 | €32,529 | ▼ 49.1% |
| Recurring financial charges65 | €43,543 | €39,976 | €37,480 | €31,656 | €28,403 | €30,447 | €63,911 | €32,529 | ▼ 49.1% |
| Profit (loss) for the period before taxes9903 | €130,042 | €100,563 | €717,827 | -€22,811 | €64,928 | €294 | -€133,408 | €110,967 | - |
| Income taxes67/77 | €31,896 | €23,360 | €44,026 | €397 | €12,303 | €2,644 | - | €2,595 | - |
| Profit (loss) for the period9904 | €98,146 | €77,204 | €673,801 | -€23,208 | €52,625 | -€2,350 | -€133,408 | €108,372 | - |
| Profit (loss) for the period to be appropriated9905 | €98,146 | €77,204 | €673,801 | -€23,208 | €52,625 | -€2,350 | -€133,408 | €108,372 | - |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €2.9m | €2.8m | €2.9m | €3.1m | €3.1m | €3.1m | €3.0m | €3.1m | ▲ 4.8% |
| Fixed assets21/28 | €2.8m | €2.7m | €2.3m | €2.4m | €2.4m | €2.3m | €2.3m | €2.3m | ▼ 0.7% |
| Tangible fixed assets22/27 | €0.5m | €0.5m | €0.5m | €0.5m | €0.5m | €0.4m | €0.4m | €0.4m | ▼ 4.1% |
| Land and buildings22 | - | - | - | €0.5m | €0.4m | €0.4m | €0.4m | €0.4m | ▼ 4.5% |
| Plant, machinery and equipment23 | - | - | - | €181 | €8 | - | - | €0.007m | - |
| Furniture and vehicles24 | - | - | - | €0.02m | €0.02m | €0.01m | €0.006m | - | - |
| Financial fixed assets28 | €2.3m | €2.3m | €1.8m | €1.9m | €1.9m | €1.9m | €1.9m | €1.9m | = |
| Current assets29/58 | €0.2m | €0.1m | €0.6m | €0.7m | €0.7m | €0.7m | €0.7m | €0.8m | ▲ 23.7% |
| Amounts receivable within one year40/41 | €0.2m | €0.1m | €0.6m | €0.7m | €0.7m | €0.7m | €0.1m | €0.7m | ▲ 568% |
| Trade receivables40 | - | - | - | €0.05m | €0.08m | €0.02m | €0.03m | €0.05m | ▲ 101% |
| Other amounts receivable41 | - | - | - | €0.6m | €0.7m | €0.7m | €0.08m | €0.7m | ▲ 719% |
| Cash at bank and in hand54/58 | €0.01m | €0.001m | €0.04m | €84 | €0.003m | - | €0.6m | €0.1m | ▼ 81.6% |
| Deferred charges and accrued income490/1 | - | - | - | €443 | - | - | €0.01m | €0.001m | ▼ 88.4% |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €2.9m | €2.8m | €2.9m | €3.1m | €3.1m | €3.1m | €3.0m | €3.1m | ▲ 4.8% |
| Equity10/15 | €0.3m | €0.4m | €1.0m | €1.0m | €1.1m | €1.1m | €0.4m | €0.5m | ▲ 27.9% |
| Contributions10/11 | €0.03m | €0.03m | - | €0.03m | €0.03m | €0.03m | €0.03m | €0.03m | = |
| Reserves13 | €0.003m | €0.003m | €0.003m | €0.003m | €0.003m | €0.003m | €0.4m | €0.5m | ▲ 29.8% |
| Distributable reserves133 | - | - | - | €0.003m | €0.003m | €0.003m | €0.4m | €0.5m | ▲ 29.8% |
| Profit (loss) carried forward14 | €0.3m | €0.3m | €1.0m | €1.0m | €1.0m | €1.0m | - | - | - |
| Amounts payable17/49 | €2.6m | €2.5m | €1.9m | €2.0m | €2.0m | €2.0m | €2.6m | €2.6m | ▲ 1.3% |
| Amounts payable after more than one year17 | €1.8m | €1.6m | €1.4m | €1.3m | €1.1m | €1.0m | €0.8m | €2.1m | ▲ 172% |
| Financial debts170/4 | - | - | - | €1.3m | €1.1m | €1.0m | €0.8m | €2.1m | ▲ 172% |
| Amounts payable within one year42/48 | €0.8m | €0.9m | €0.5m | €0.8m | €0.9m | €1.0m | €1.8m | €0.5m | ▼ 70.0% |
| Current portion of amounts payable after more than one year42 | - | - | - | €0.2m | €0.2m | €0.2m | €0.08m | €0.08m | ▲ 1.2% |
| Financial debts43 | - | - | - | €0.01m | €0.008m | €0.02m | - | - | - |
| Credit institutions430/8 | - | - | - | €0.01m | €0.008m | €0.02m | - | - | - |
| Trade debts44 | €0.01m | €0.02m | €0.04m | €0.005m | €0.002m | €0.01m | €0.06m | €0.04m | ▼ 38.8% |
| Suppliers440/4 | - | - | - | €0.005m | €0.002m | €0.01m | €0.06m | €0.04m | ▼ 38.8% |
| Taxes, remuneration and social security45 | - | - | - | €0.03m | €0.009m | €0.03m | €0.06m | €0.1m | ▲ 118% |
| Taxes450/3 | - | - | - | €0.03m | €0.009m | €0.03m | €0.02m | €0.04m | ▲ 102% |
| Remuneration and social security454/9 | - | - | - | - | - | - | €0.04m | €0.1m | ▲ 126% |
| Other amounts payable47/48 | - | - | - | €0.5m | €0.7m | €0.8m | €1.6m | €0.3m | ▼ 81.7% |
| Accrued charges and deferred income492/3 | - | - | - | - | - | €0.01m | - | - | - |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €98,146 | €77,204 | €673,801 | -€23,208 | €52,625 | -€2,350 | -€133,408 | €108,372 | - |
| + Depreciation and write-downs630 | €18,216 | €18,203 | €18,316 | €23,880 | €23,727 | €23,561 | €23,555 | €18,177 | ▼ 22.8% |
| Operating cash flow (approximation) | €116,362 | €95,406 | €692,116 | €672 | €76,352 | €21,211 | -€109,853 | €126,549 | - |
| Investment in fixed assets (approximation) | - | €0 | €419,895 | -€101,676 | €2,358 | €0 | €1,500 | -€1,600 | - |
| Change in cash | - | -€9,447 | €34,540 | -€35,515 | €2,542 | - | - | -€449,033 | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Latest 10 of 16 filings with the National Bank
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | abbreviated format | 28-07-2026 | 2026-00360332 | |
| 31-12-2024 | abbreviated format | 30-09-2025 | 2025-00520481 | |
| 31-12-2023 | abbreviated format | 30-08-2024 | 2024-00434289 | |
| 31-12-2022 | abbreviated format | 27-07-2023 | 2023-00277872 | |
| 31-12-2021 | abbreviated format | 28-07-2022 | 2022-20234168 | |
| 31-12-2020 | abbreviated format | 23-08-2021 | 2021-53500299 | |
| 31-12-2019 | abbreviated format | 26-08-2020 | 2020-45200414 | |
| 31-12-2018 | abbreviated format | 26-07-2019 | 2019-41800383 | |
| 31-12-2017 | abbreviated format | 30-07-2018 | 2018-42700193 | |
| 31-12-2016 | abbreviated format | 28-07-2017 | 2017-39800218 |
Board & ownership
Directors
Directors
1 director, last change in 2024
Board 1
AMBIXX BV
Current
Director · appointed in the act of 09-07-2024 · Legal entity · permanent representative: Marleen Slaets · listed in the 2025 annual accounts, filed on 28-07-2026
Permanent representatives 1
Marleen Slaets
Current
Permanent representative · appointed in the act of 09-07-2024 · for AMBIXX BV
Owners and capital
Shareholders
1 ownerChain of control
- AMBIXX
- E-pharma
Owners 1
- AMBIXXparentSourceaccounts AMBIXX 2025Equity €4.0m Loss of €195,005 in 2025 (profit of €535,946 in 2024) Checked score 87100%
Mandate history
2 people, 1 in office
- Board
- began earlier
| Name | Functions and periods |
|---|---|
| AMBIXX BV |
|
| Erik VAN NUFFEL |
|
Network & group
Holdings and subsidiaries
3 holdingsHoldings 3
Source for every holding own accounts 2025
- Apotheek CauwenberghsubsidiaryEquity -€15,977 Loss of €219,682 in 2025 (profit of €21,947 in 2024) Checked score 53100%
- Apotheek De VoogtsubsidiaryEquity €157,130 Loss of €90,615 in 2025 (profit of €30,284 in 2024) Checked score 64100%
- APOTHEEK ZWAANTJEsubsidiaryEquity €44,525 Loss of €13,589 in 2025 (profit of €26,489 in 2024) Checked score 66100%
Companies at the same address
3 other companiesConnections & network
1 current directorThe network starts from the directors of E-pharma. Every other company they run is a node.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Timeline
Acts, filings and financial milestones
Deadline for the 2026 accounts:
2026
28-07
abbreviated format · 3 days before the deadline
2025
31-12
Financial
Back to profitnet €108,372
The net result is €108,372, after 2 loss-making years.
31-12
Financial
Liquidity more than quadruplescurrent ratio 1.51
The current ratio rises from 0.37 to 1.51. Short-term debt falls from €1.8m to €548,811.
30-09
abbreviated format · 61 days late
2024
31-12
Financial
Weakest financial yearnet -€133,408
The net result drops to -€133,408, the lowest from 2018 to 2025. It recovers the following year.
30-08
abbreviated format · 30 days late
09-07
Gazette deed
Resignation: Erik VAN NUFFEL (director)Appointment: AMBIXX BV (director) · Permanent representative: Marleen Slaets3 points ▸
Gazette deed
Resignation: Erik VAN NUFFEL (director)
Appointment: AMBIXX BV (director) · Permanent representative: Marleen Slaets3 points ▸
- Director resignation, Erik VAN NUFFEL (director)
- Director appointment, AMBIXX BV (director)
- Permanent representative, Marleen Slaets
2023
27-07
abbreviated format · 4 days before the deadline
2022
31-12
Financial
Back to profitnet €52,625
The net result is €52,625, after one loss-making year.
28-07
abbreviated format · 3 days before the deadline
2021
23-08
abbreviated format · 23 days late
2020
31-12
Financial
Highest result from 2018 to 2025net €673,801 ▲773%
The operating result of €225,722 and the net result of €673,801 are both a record.
Show earlier events
31-12
Financial
Liquidity more than 12 timescurrent ratio 1.39
The current ratio rises from 0.11 to 1.39. Short-term debt falls from €855,562 to €464,018.
31-12
Financial
Equity above €1mequity €1.0m ▲187%
With a profit in every financial year since 2018, equity grows to €1.0m.
26-08
abbreviated format · 26 days late
2019
26-07
abbreviated format · 5 days before the deadline
2018
30-07
abbreviated format · 1 day before the deadline
2017
28-07
abbreviated format · 3 days before the deadline
2009
04-12
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Register details
Identity
KBO recordName
E-pharma in Dutch
Enterprise number
0821.059.072
Legal form
Private limited company
Status
Active, normale toestand
Founded
02-12-2009
Entity type
Legal entity
Registered office and establishments
Registered office
Heidestraat 217, 2660 Antwerpen, Belgium
Establishment unit
E-pharma, Heidestraat 217, 2660 Antwerpen since 02-12-2009 · unit number 2.183.525.32947730 Retail sale of pharmaceutical products
Activities
NACEBEL 2025VAT activities
64210
Activities of holding companies main activity
63920
Other information service activities
Social security (RSZ) activities
47730
Retail sale of pharmaceutical products main activity
Codes under NACEBEL 2008
VAT activities
64200
Holdings main activity
63990
Computing infrastructure, data processing, hosting and other information service activities
Social security (RSZ) activities
47730
Retail trade main activity
Joint committee
313 Paritair Comité voor de apotheken en tarificatiediensten annual accounts 2025
Invoicing and payment
VAT number
BE 0821.059.072
Financial year and general meeting
Accounts at the NBBFinancial year end
31-12
Sites & property
Location
Buildings and parcels at the address
Ground area
501 m²
Building footprint
158 m²
Building volume
1,392 m³
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 11019B0225/00W000 | Flanders | 501 m² | 1 · 158 m² | 11.9 m · 3 |